CNR1 and obesity disorder: Rimonabant, a representative CB1 antagonist [65–67], was approved by the European Medicines Agency in 2006 to reduce appetite via CB1 receptor antagonism in the brain, as an adjunct to diet and exercise in the treatment of obesity [68, 69].